{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Fantasia KL"],"funding":["NCATS NIH HHS","NIDDK NIH HHS"],"pagination":["1010-1017"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8442173"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(5)"],"pubmed_abstract":["<h4>Background</h4>Limited data exist regarding diabetes technology use among adults with type 1 diabetes (T1D) in urban racially/ethnically diverse safety-net hospitals. We examined racial/ethnic differences in the use of continuous glucose monitor (CGM) and continuous subcutaneous insulin infusion (CSII) in this setting.<h4>Methods</h4>A retrospective review of 227 patients ≥ 18 years of age with T1D seen in an urban, safety-net endocrinology clinic during 2016-2017 was completed (mean age: 39; 80% English-speaking; 50% had public insurance). Diabetes technology use, defined as either CGM or CSII or both CGM and CSII, and clinical outcomes were examined by race/ethnicity.<h4>Results</h4>Overall, 30% used CGM and 26% used CSII. After adjusting for age, language, insurance, and annual income, diabetes technology use in non-White patients was significantly lower than in White patients, predominantly lower in Black (aOR 0.25 [95% CI 0.11-0.56]) and patients identified as other race/ethnicity (aOR 0.30 [95% CI 0.11-0.77]). At the highest household income level (≥$75,000/y), Black and Hispanic individuals were significantly less likely than White individuals to use diabetes technology (<i>P</i> < .0007). Mean hemoglobin A1c (HbA1c) was lower in patients using any diabetes technology compared with patients using no technology (<i>P</i> < .0001). Use of CGM and CSII together was associated with the lowest HbA1c across all racial/ethnic groups.<h4>Conclusions</h4>Racial/ethnic disparities in diabetes technology use and glycemic control were observed even after adjusting for sociodemographic factors. Further research should explore barriers to accessing diabetes technology in non-White populations."],"journal":["Journal of diabetes science and technology"],"pubmed_title":["Racial Disparities in Diabetes Technology Use and Outcomes in Type 1 Diabetes in a Safety-Net Hospital."],"pmcid":["PMC8442173"],"funding_grant_id":["UL1 TR001430","T32 DK007201"],"pubmed_authors":["Lee C","Rizo I","Fantasia KL","Wirunsawanya K"],"additional_accession":[]},"is_claimable":false,"name":"Racial Disparities in Diabetes Technology Use and Outcomes in Type 1 Diabetes in a Safety-Net Hospital.","description":"<h4>Background</h4>Limited data exist regarding diabetes technology use among adults with type 1 diabetes (T1D) in urban racially/ethnically diverse safety-net hospitals. We examined racial/ethnic differences in the use of continuous glucose monitor (CGM) and continuous subcutaneous insulin infusion (CSII) in this setting.<h4>Methods</h4>A retrospective review of 227 patients ≥ 18 years of age with T1D seen in an urban, safety-net endocrinology clinic during 2016-2017 was completed (mean age: 39; 80% English-speaking; 50% had public insurance). Diabetes technology use, defined as either CGM or CSII or both CGM and CSII, and clinical outcomes were examined by race/ethnicity.<h4>Results</h4>Overall, 30% used CGM and 26% used CSII. After adjusting for age, language, insurance, and annual income, diabetes technology use in non-White patients was significantly lower than in White patients, predominantly lower in Black (aOR 0.25 [95% CI 0.11-0.56]) and patients identified as other race/ethnicity (aOR 0.30 [95% CI 0.11-0.77]). At the highest household income level (≥$75,000/y), Black and Hispanic individuals were significantly less likely than White individuals to use diabetes technology (<i>P</i> < .0007). Mean hemoglobin A1c (HbA1c) was lower in patients using any diabetes technology compared with patients using no technology (<i>P</i> < .0001). Use of CGM and CSII together was associated with the lowest HbA1c across all racial/ethnic groups.<h4>Conclusions</h4>Racial/ethnic disparities in diabetes technology use and glycemic control were observed even after adjusting for sociodemographic factors. Further research should explore barriers to accessing diabetes technology in non-White populations.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Sep","modification":"2025-04-22T22:04:26.987Z","creation":"2025-04-06T03:55:00.864Z"},"accession":"S-EPMC8442173","cross_references":{"pubmed":["33719610"],"doi":["10.1177/1932296821995810"]}}